自体造血干细胞移植治疗恶性血液病

Clinical Study of Autologous Hematopoietic Stem Cell Transplantation for Hematological Malignancies

目的：评价自体造血干细胞移植（AHSCT）治疗恶性血液病的临床疗效。方法：回顾分析36例行AHSCT患者的临床资料。其中14例在移植后进行维持治疗。结果：36例AHSCT患者均重建造血,无移植相关死亡。中位随访时间为18（1~38）个月,存活29例（80.6%）,复发7例（19.4%）,患者3年总生存率（OS）和无病生存率（DFS）分别是76%和62%。AH-SCT后维持治疗者未见复发。结论：AHSCT是治疗恶性血液病的有效手段,移植前患者的疾病状态是影响移植后复发的主要因素,移植后的维持治疗能有效地降低复发率。

Objective：To evaluate the clinical efficacy of autologous hematopoietic stem cell transplantation（AHSCT） for hematological malignancies.Methods： Thirty-six cases performing AHSCT were analysed restrospectively.Forteen of 36 patients received maintenance therapy after AHSCT.Results： All the patients were successfully engrafted.None of them had the transplantation-related mortality.The median follow up duration was 18（1-36） months.Twenty-nine of 36 patients were still alive during the analysis.The 3 years overall survival（OS） rate and disease free survival（DFS） rate patients were 76% and 62%.There were no relapse patient in the maintenance therapy post-AHSC.Conclusions： AHSCT is a good treatment for hematological malignancies.The morbid state before AHSCT is a main cause for relapse post-AHSCT,and the maintenance therapy post-AHSCT is able to decrease relapse effectively.